Pfizer Inc.

Pfizer Inc., headquartered in New York, is a for-profit pharmaceutical manufacturer that sells pharmaceutical preparations and biologicals to the federal government as a prime contractor, competing on a full-and-open basis across 6,660 recent prime awards valued at $98.93 billion in combined potential value. The vendor operates with no SBA set-aside designations and does not pursue federal business through set-aside categories; all work reflects commercial pricing and standard federal procurement terms.

Pfizer's federal footprint centers on vaccine procurement and pharmaceutical supply to military medical logistics and federal health agencies. The company holds major indefinite-delivery contracts with the Centers for Disease Control and Prevention for adult vaccines (ceiling $112.8 million, effective through June 30, 2027) and pediatric COVID-19 vaccines under the Vaccine for Children program (ceiling $764.2 million, effective through May 31, 2027). On the supply side, Pfizer delivers individual pharmaceutical products—fentanyl, lidocaine, ceftriaxone, Solu-Medrol, and dozens of injectable and oral medications—through thousands of small delivery orders placed by the Defense Logistics Agency's Medical Supply Chain (5,558 awards), the Department of Veterans Affairs, and the Defense Commissary Agency. Recent representative work includes a $542.6 thousand BPA call from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response for sterile water for injection (award date May 15, 2026, completion through May 14, 2027) and a $24.7 thousand delivery order from DLA Medical Supply Chain for Procardia XL tablets (awarded May 13, 2026, completing May 14, 2026).

Customer concentration is extreme. The DLA Troop Support Medical supply operation alone accounts for 5,558 awards (83% of award count) but only $223.7 million in combined potential value, reflecting the high-velocity, low-dollar-per-order character of pharmaceutical supply-chain delivery orders. By dollar value, concentration shifts dramatically: CDC Pittsburgh ($26.61 billion combined potential value across 42 awards) and the VA Veterans Health Administration Veterans Integrated Service Network 12 ($21.81 billion across 35 awards) anchor the federal revenue base. Together, the top five customer segments represent 90% of awards and 59% of combined potential value. The mismatch between volume concentration (DLA Medical) and dollar concentration (CDC and VA vaccines) reflects Pfizer's dual role as a high-velocity commodity supplier for military medical logistics and as an exclusive or principal vendor for large vaccine procurements.

Pfizer sits on multiple indefinite-delivery vehicles. The largest is Indefinite Delivery Contract SPE2D020D0014 (4,716 task orders, $7 million combined potential value), followed by SPM2D012D0022 (768 task orders, $4.5 million). The vendor also holds seats on two Federal Supply Schedules—V797P5883X (428 task orders, $7.7 million) and V797P5547M (138 task orders)—along with a vehicle branded "Pharmaceuticals and Drugs" (185 task orders, $12.2 million). These vehicles are conduits for recurring pharmaceutical and vaccine orders; the award volume per vehicle masks the relatively modest individual transaction size in most cases.

Activity has remained stable over the past five years, averaging 730 awards annually (2022: 867; 2023: 678; 2024: 640; 2025: 705; 2026: 858 through August). The recompete exposure in the next 24 months is minimal: only 2 awards worth a combined $2.7 million face ultimate completion inside that window, reflecting the long-term or evergreen character of most Pfizer vaccine and supply contracts.

The vendor's award portfolio is almost entirely prime (6,660 of 6,662 awards, or 100%). Pfizer records only 2 sub-award entries in the source data, both grant sub-awards: one sub-grant from the State of Wisconsin Department of Health Services for SCHIP vaccine purchase (award date August 27, 2026). The vendor does not appear in the federal award data as a named subcontractor to other primes; its federal strategy centers on direct prime relationships with customer agencies and placement of task orders under established supply-chain IDIQs and schedules.

Pfizer's federal services activity reported in the Service Contract Inventory is negligible: $460 thousand in SCI-reportable invoicing in FY2022 only, with effectively zero SCI-recorded revenue thereafter (FY2023–FY2025). SCI covers service contracts above the $150,000 threshold and excludes goods and products; Pfizer's federal work consists almost entirely of pharmaceutical goods sales rather than services, explaining the minimal SCI footprint. The hourly rate recorded in SCI (derived from the single FY2022 contract) was $2,301.39 per hour, likely reflecting a specialized pharmaceutical consulting or technical support arrangement rather than the vendor's primary business model.

The vendor operates through multiple named subsidiaries including Wyeth, King Pharmaceuticals, Meridian Medical Technologies, Array Biopharma, and Greenstone LLC, though award data does not systematically distinguish which subsidiary performs individual federal contracts. The corporate structure reflects Pfizer's acquisition history and geographic or therapeutic diversification rather than a distinct set-aside or market-segment strategy within federal procurement.

Pfizer competes in pharmaceutical preparation manufacturing (NAICS 325412) and medicinal and botanical manufacturing (NAICS 325411), with 5,365 and 858 awards respectively. The PSC profile is dominated by Drugs and Biologicals (PSC 6505, 6,365 awards), with remainder in medical and surgical instruments and supplies. The vendor faces no visible recompete cliff; its largest contracts (the CDC vaccine IDIQs) extend through mid-2027 and appear to be recurring vehicles where replacement is a routine solicitation process rather than an expiring-contract crisis.